Gilpin Wealth Management’s ANI Pharmaceuticals ANIP Stock Holding History

Gilpin Wealth Management’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$146	Hold	2	–	–	﹤0.01%	1217
2026 Q2	$166	Hold	2	–	–	﹤0.01%	953
2026 Q1	$154	Hold	2	–	–	﹤0.01%	908
2025 Q4	$158	Buy	+2	New	+$173	﹤0.01%	721

Other funds holding ANIP

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.5B AUM 61.77% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Gilpin Wealth Management's ANIP Position: Q3 2026 in Review

Gilpin Wealth Management held its ANI Pharmaceuticals (ANIP) position steady in Q3 2026 at 2 shares worth $146. The position accounts for ﹤0.01% of the portfolio, ranked #1217.

Gilpin Wealth Management first reported a position in ANIP in Q4 2025 and has held it in 4 quarters since. The position peaked at $166 in Q2 2026. 6 funds tracked by Wall St. Rank hold ANIP as of Q3 2026.

Gilpin Wealth Management held 2 shares of ANI Pharmaceuticals worth $146 as of Q3 2026.
Gilpin Wealth Management left its ANI Pharmaceuticals share count unchanged in Q3 2026.
ANI Pharmaceuticals made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1217 holding.
Gilpin Wealth Management first reported a position in ANI Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
Gilpin Wealth Management's ANI Pharmaceuticals position peaked at $166 in Q2 2026.
6 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.